Company Overview

Sharps Technology, Inc. is a publicly traded medical device company focused on the design, manufacture, and commercialization of advanced safety syringe systems. The company operates within the medical devices and healthcare supplies industries, with a specific emphasis on single-use, safety-engineered injection solutions intended to reduce needlestick injuries, reuse, and cross-contamination. Its core products are targeted primarily at hospitals, clinics, pharmaceutical companies, and public health organizations.

The company’s primary revenue drivers are its proprietary smart safety syringe platforms, including the Sharps Pro™ and Sharps Solo™ product lines, which integrate passive safety mechanisms and tamper-resistant features. Sharps Technology positions itself around manufacturing scalability, regulatory compliance, and supply-chain reliability, particularly for customers seeking alternatives to traditional syringe suppliers. The company traces its current form to a corporate restructuring and rebranding completed in 2017, when it shifted focus from renewable energy activities to medical devices and injection safety technologies.

Business Operations

Sharps Technology generates revenue through the development, manufacturing, and planned commercialization of safety syringe products sold to healthcare providers, pharmaceutical partners, and government or institutional buyers. Its operations are structured around syringe design, intellectual property development, regulatory approval, and high-volume manufacturing. The company emphasizes proprietary syringe engineering that enables automated assembly and reduced per-unit costs at scale.

Manufacturing operations are primarily conducted through Sharps Technology Hungary Kft., which operates a dedicated production facility designed for high-capacity syringe manufacturing. The company maintains sales, administrative, and regulatory functions in the United States while pursuing international distribution opportunities. As of the latest publicly available disclosures, large-scale recurring commercial sales remain limited, and revenue has been largely driven by pilot programs, initial purchase orders, or development-stage commercial arrangements; longer-term revenue visibility remains dependent on customer adoption and contract execution.

Strategic Position & Investments

Sharps Technology’s strategic direction centers on becoming a scalable, alternative supplier of safety syringes amid global demand for injection safety, supply-chain diversification, and pandemic preparedness. Growth initiatives focus on expanding manufacturing capacity, securing long-term supply agreements, and pursuing regulatory clearances across multiple jurisdictions. The company has emphasized readiness to support large-volume contracts for vaccination programs and pharmaceutical filling applications.

The company’s investment activity has been concentrated on capital expenditures related to manufacturing automation, tooling, and quality systems rather than acquisitions. No material acquisitions of unrelated businesses have been disclosed in recent filings. Sharps Technology continues to invest in refining its syringe platforms to address emerging regulatory standards and customer requirements, particularly in markets emphasizing single-use and anti-reuse medical devices. Data on material joint ventures beyond its Hungarian manufacturing subsidiary is inconclusive based on available public sources.

Geographic Footprint

Sharps Technology is headquartered in the United States, with its principal executive offices located in New York. Its most significant operational footprint is in Europe, where its manufacturing subsidiary operates in Hungary, providing access to skilled labor, centralized European logistics, and proximity to key healthcare markets.

The company’s commercial focus spans North America, Europe, and selected international markets, particularly where public health agencies and pharmaceutical companies seek reliable safety syringe supply. While global in ambition, Sharps Technology’s international market penetration remains in development, and its operational influence outside Europe and the United States is primarily through prospective customers and distribution discussions rather than established large-scale sales networks.

Leadership & Governance

Sharps Technology is led by an executive team with experience in medical devices, manufacturing, and public-company operations. Leadership has emphasized disciplined scaling, regulatory compliance, and long-term positioning within the global injection safety market. The company operates under a standard U.S. public-company governance framework, with oversight from a board of directors.

Key executives include:

• Robert Hayes – Chief Executive Officer
• Data inconclusive based on available public sources – Additional executive leadership roles, including Chief Financial Officer and other senior officers, are disclosed in SEC filings, but publicly reported information across sources is not fully consistent regarding current incumbents and titles.

The leadership’s stated strategic vision centers on establishing Sharps Technology as a dependable, high-volume manufacturer of next-generation safety syringes while addressing systemic supply risks in global healthcare markets.